ArticleScientific reports2025
Cell free supernatants of Bifidobacterium adolescentis and Bifidobacterium longum suppress the tumor growth in colorectal cancer organoid model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Human papillomavirus (HPV) infection and prevalence of colorectal cancer: an updated systematic review and meta-analysis of global data.International journal of surgery (London, England) · 2026Pooled it
- Exploring the Adhesion Potential ofFoods (Basel, Switzerland) · 2026Article
- Gut Bacteria: A Beneficial Symbiosis or a Hidden Threat? Investigating the Dual Role of Bacteria in Gastrointestinal Diseases.Current microbiology · 2026Review
- Bacteriophage-mediated restoration of epithelial integrity, DNA damage response, and transcriptomic homeostasis in colon organoids exposed to ETBF and pks + E. coli.Scientific reports · 2026Article
- Postbiotics as Multifunctional Bioactives: Mechanistic Insights and Translational Applications in Host Physiology and Microbial Ecosystem Modulation.Microorganisms · 2026Review
- Assessment of genome evolution inmSystems · 2026Article
- Bacteroides ovatus Has the Potential to Be a Next-Generation Probiotic Strain.Probiotics and antimicrobial proteins · 2026Review
- Postbiotics: emerging bioactive agents in cancer therapy.Cancer biology & medicine · 2026Review
- Gut microbiome in colorectal cancer: recent advances and clinical implications.Annals of coloproctology · 2026Review
- Article
- Genome-guided prebiotic fermentation generates anti-virulence metabolites againstFrontiers in microbiology · 2026Article
- Gut microbiome in gastrointestinal neoplasms: from mechanisms to precision therapeutic strategies.Gut pathogens · 2025Review
- The release patterns and potential prebiotic characteristics of soluble and insoluble dietary fiber-bound polyphenols from pinot noir grape pomaceFood chemistry: X · 2025Article
- Gut Microbiota and Colorectal Cancer: A Balance Between Risk and Protection.International journal of molecular sciences · 2025Review
- Microbial molecules, metabolites, and malignancy.Neoplasia (New York, N.Y.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The probiotic gut microbiome and its metabolites are pivotal in regulating host metabolism, inflammation, and immunity. Host genetics, colonization at birth, the host lifestyle, and exposure to diseases and drugs determine microbial composition. Dysbiosis and disruption of homeostasis in the beneficial microbiome have been reported to be involved in the tumorigenesis and progression of colorectal cancer (CRC). However, the influence of bacteria-secreted metabolites on CRC growth is yet to be fully elucidated. In this study, we compared the microbial composition of CRC patients to healthy controls to identify distinct patterns of microbiota-derived metabolites in CRC patients. Metagenomic analysis demonstrated that beneficial bacteria strains; Blautia producta, Bifidobacterium adolescentis, and Bifidobacterium longum decreased, while Parabacteroides distasonis and Bacteroides ovatus were more prevalent in the CRC patient group. Treatment of cancer organoid lines with microbial culture supernatants from Blautia producta, Bifidobacterium adolescentis, and Bifidobacterium longum showed remarkable inhibition of cancer growth. This study demonstrates that the bacterial metabolites depleted in CRC patients may inhibit cancer growth and highlights the effects of microbiome-derived metabolites on CRC growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.